Patents Examined by Jeffrey Stucker
  • Neuropilin antagonists
    Patent number: 7994286
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: August 9, 2011
    Assignee: Genentech, Inc.
    Inventors: Ryan J. Watts, Yan Wu
  • Human E3? ubiquitin ligase family
    Patent number: 7994291
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Hui-Quan Han, Keith Kwak
  • Fully human monoclonal antibodies to IL-13
    Patent number: 7994302
    Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 9, 2011
    Assignee: Amgen Inc.
    Inventors: Ian Foltz, Raffaella Faggioni, Giorgio Senaldi, Kathy Manchulenko, Jaspal S. Kang, Palaniswami Rathanaswami, Kiran Ahluwalia, Orit Foord, Scott Klakamp
  • Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
    Patent number: 7994131
    Abstract: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, injury or disease.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: August 9, 2011
    Assignee: Stem Cell Therapeutics Corp.
    Inventor: Joseph Tucker
  • Markers for brain damage
    Patent number: 7985555
    Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: July 26, 2011
    Assignee: Washington University
    Inventors: Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
  • Preparation of insulin conjugates
    Patent number: 7977454
    Abstract: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: July 12, 2011
    Assignee: Biocon Limited
    Inventors: Partha Hazra, Manjunath Hadavanahalli Shivarudraiah, Anand Khedkar, Harish Iyer, Nitesh Dave, Gautam Krishnan, Shrikumar Suryanarayan
  • Glial mitogenic factors, their preparation and use
    Patent number: 7968678
    Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: June 28, 2011
    Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Multimeric complexes of antigens and an adjuvant
    Patent number: 7951376
    Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: May 31, 2011
    Assignee: Imaxio
    Inventors: Fergal Hill, Jean-Baptiste Marchand, Laurence Dumon
  • Method of detecting a neuromyelitis optica specific-autoantibody by an antigenic aquaporin-4 polypeptide
    Patent number: 7947254
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: May 24, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Thomas J. Kryzer
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Patent number: 7943574
    Abstract: The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: May 17, 2011
    Assignee: Xigen SA
    Inventor: Christophe Bonny
  • Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue
    Patent number: 7939078
    Abstract: Co-administration of an effective amount of autoantigen and UV light to mucosal associated lymphatic tissue (MALT) in a patient.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: May 10, 2011
    Assignee: Codman & Shurtleff
    Inventors: Thomas M. DiMauro, Mohamed Attawia, Sean Lilienfeld, Chantal Holy
  • Human BNP immunospecific antibodies
    Patent number: 7939069
    Abstract: The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: May 10, 2011
    Assignee: Abbott Laboratories
    Inventors: Susan E. Brophy, Joan D. Tyner, Bryan C. Tieman
  • Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
    Patent number: 7935339
    Abstract: The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: May 3, 2011
    Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Ana Martin-Villalba, Peter Krammer, Deana Demjen
  • Pantropic neurotrophic factors
    Patent number: 7935671
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: May 3, 2011
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • Semaphorin genes (I)
    Patent number: 7932352
    Abstract: The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, transformed cells into which said expression vectors have been introduced, methods for producing a recombinant protein which employ said transformed cells, antisense nucleotides against the above genes, transgenic animals involving insertion or deletion of the above genes, and screening methods for antagonists of the above proteins, all of which are useful mainly in diagnoses, treatments, or studies relating to neurological diseases. The present invention further provides use of such proteins, peptides, antibodies, genes, or antisense nucleotides as pharmaceutical or diagnostic agents or laboratory reagents.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: April 26, 2011
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Shinobu Inagaki, Tatsuo Furuyama
  • Use of neuropeptides for traumatic cartilage injury
    Patent number: 7928059
    Abstract: Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: April 19, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ray Vanderby, Kelley W. Grorud
  • Parkin interacting polypeptides and methods of use
    Patent number: 7927786
    Abstract: The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: April 19, 2011
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stefan M. Pulst, Duong P. Huynh
  • Methods compositions and compound assays for inhibiting amyloid-beta protein production
    Patent number: 7910320
    Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: March 22, 2011
    Assignee: Galapagos N.V.
    Inventors: Pascal Gerard Merchiers, Marcel Hoffman, Koenraad Frederik Florentina Spittaels
  • Treatment and prevention of vascular dementia
    Patent number: 7897575
    Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: March 1, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John M. Hallenbeck, Hideaki Wakita
  • Method of detecting or diagnosing of a neurodegenerative disease or condition
    Patent number: 7892751
    Abstract: A neurodegenerative disease or condition is diagnosed in a subject by obtaining a sample of cerebral spinal fluid from the subject and assaying the sample by an assay method that detects the presence of at least one antiphospholipid autoantibody in the sample, wherein an elevated level of at least one antiphospholipid autoantibody in the sample of cerebral spinal fluid correlates with a neurodegenerative disease or condition in the subject. The neurodegenerative disease or condition may also be diagnosed by assaying a sample of cerebral spinal fluid to detect nitrosylated antibodies, wherein an elevated level of nitrosylated antibodies correlates with a neurodegenerative disease or condition in said subject.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 22, 2011
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre